27
2021-08
Kintor Pharma Announces 2021 Interim Results
Suzhou, August 27, 2021 — Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced its 2021 interim results and released an update on its recent progress in clinical development, commercialization (including license-out and production capacity expansion), and activities in Hong Kong capital market.
25
2021-08
Suzhou, August 25 2021-- Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that it has entered into a licensing agreement with PT Etana Biotechnologies Indonesia, on the commercialization of proxalutamide for the treatment of COVID-19 in Indonesia.
20
2021-08
Inclusion of Kintor as a Constituent Stock of HSCI
Suzhou, August 20, 2021 — Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company’s stock has been included in the Hang Seng Composite Index, effective September 6, 2021.
28
2021-07
Suzhou, July 28, 2021 — Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company has dosed the first batch of subjects in its phase I clinical trial of GT20029 in China.
16
2021-07
Suzhou, July 16, 2021 - Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that Paraguay’s Ministry of Public Health and Social Welfare (MSPBS) has granted an emergency use authorization (EUA) for proxalutamide to treat hospitalized patients with COVID-19 infections at the MSPBS hospitals.
15
2021-07
Suzhou, July 15, 2021-- Kintor Pharmaceutical Limited (HKEX:9939) today announced that it has entered into a licensing agreement with Shanghai Fosun Pharmaceutical Development Ltd. ("Fosun Pharma Development"), on the commercialisation of proxalutamide for the treatment of COVID-19 indication in India and 28 African countries (the"Collaboration Regions"). Kintor and Fosun Pharma Development will collaborate on the development, promotion, and sales of proxalutamide for the treatment of COVID-19 indication.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn